The association between low glucose-6-phosphate dehydrogenase activity level and hepatitis B virus infection among pre-pregnant reproductive-age Chinese females

Jun Zhao1,2, Xu Zhang3, Ting Guan4, Qiaoyun Dai1,2, Wenshan He4, Hongguang Zhang1,2, Yuanyuan Wang1,2, Bei Wang5, Zuqiu Peng1,2, Xuhuai Hu4, Daxun Qi1,2, Xueying Yang3,2, Yue Zhang4,6 & Xu Ma1,2,6

The relationship between females with low glucose-6-phosphate dehydrogenase activity level (LG6PD) and HBV infection is unclear. We conducted a cross sectional study of 124,406 reproductive-age Chinese females who participated in the National Free Pre-conception Check-up Projects to investigate the risk of HBV infection among females with LG6PD and its effect on liver enzyme. Based on HBV serological test results, the participants were divided into the susceptible, immunized, and HBV infected groups. The multivariable-adjusted odds ratios (ORs) for HBV infection in LG6PD participants were 1.71 (95% confidence interval (CI): 1.45–2.01) and 1.41 (95% CI: 1.23–1.62), respectively with the susceptible and immunized participants as references, compared to those without LG6PD. Participants with HBV infection only and combined with HBV infection and LG6PD had 184% and 249% significantly higher risks of elevated alanine transaminase (ALT) (susceptible participants as reference). If the immunized participants were used as reference, significant higher odds of elevated ALT occurred (3.48 (95% CI: 3.18–3.80), 4.28 (95% CI: 2.92–6.28)). Thus, reproductive-age females with LG6PD had a higher prevalence of HBV infection, and LG6PD might exacerbate ALT elevation in HBV infected females. Our findings underscore the need to explore collaborative management approaches for these two diseases among reproductive-age females for maternal and child health.

Low glucose-6-phosphate dehydrogenase activity level (LG6PD) is one of typical features of G6PD deficiency, which is an X-linked incomplete dominant inheritance of red blood cell enzyme disease, as well as one of the most common causes of hemolytic anemia1,2. Reports indicate that more than 400 million people are affected by G6PD deficiency worldwide1. According to the population monitoring results of 2016 annual Chinese maternal and child health monitoring report, G6PD deficiency ranked second highest among all birth defects3. Most provinces in China had included the G6PD enzyme activity test program in neonatal screening. Previous studies showed that LG6PD was associated with reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is an important antioxidant in humans4. Low levels of NADPH bring about oxidative stress disorder which could result in dysfunctional granulocytes5 and thus enhance the susceptibility to viral infections2,6,7.

1National Research Institute for Family Planning, Beijing, China. 2National Human Genetic Resources Center, Beijing, China. 3Department of medical record management, The Affiliated YanAn Hospital of Kunming Medical University, Yunnan, China. 4Shenzhen Health Development Research Center, Guangdong, China. 5School of Public Health, Southeast University, Jiangsu, China. 6Graduate School of Peking Union Medical College, Beijing, China. Jun Zhao and Xu Zhang contributed equally. Correspondence and requests for materials should be addressed to X.M. (email: genetic88@sina.com)
Hepatitis B virus (HBV) infection and its related complications are a primary public health threat worldwide\(^2\). An estimated 2 billion people have been infected with HBV globally, and more than 257 million are chronic carriers of the virus\(^3\). China has a huge population base (1.374 million in 2015)\(^4\) and a continuing burden of HBV infection (with about 90 million hepatitis B surface antigen (HBsAg) positive (HBsAg(+) people)\(^5\), which is known as the primary driver of the global prevalence of HBV infection\(^6\).

A previous population study suggested that individuals with G6PD deficiency were twice as likely to acquire HBV infection as those without G6PD deficiency\(^6\). However, Chen et al.\(^7\) suggested that G6PD might be an endogenous promoting factor for HBV replication, which participates in and influences the replication process through interferon stimulated gene pathways. Considering the mother-to-child transmission is one of the main transmission routes of HBV, and the liver burden of HBV infected females could be aggravated during their pregnancy period, furthermore, the risk of spontaneous abortion, preterm labor and other adverse pregnancy outcomes might also increase\(^8\). Therefore, it is necessary to study the role of LG6PD in HBV infection and its effect on liver enzyme among pre-pregnant reproductive-age females to improve the health of both mothers and children.

Shenzhen is a city located in the southern coast of Guangdong province, China, where the prevalence of G6PD deficiency (1.14~3.68\%)\(^9\)\(^10\) and HBV infection (7.1\% HBsAg(+)\(^11\)\(^12\)) are both high in female population. Therefore, we carried out a cross sectional study to investigate the relationship between LG6PD and HBV infection in Shenzhen among reproductive-age females who participated in the National Free Pre-conception Check-up Projects (NFPCP), which is a national health service supported by the Chinese government\(^13\).

The primary objective of this study was to test the hypothesis that reproductive-age females with LG6PD have a higher prevalence of HBV infection. The secondary objective was to explore the effect influence of LG6PD on liver enzyme among HBV infected females.

**Methods**

**Participants and study design.** The NFPCP is a nationwide, population-based cross-sectional study project aimed at providing free pre-pregnancy medical examinations for reproductive-age couples who have made their conception plan in 6 months\(^2\). The overall goal of the project is to reduce the incidence of adverse pregnancy outcomes throughout the country. Trained local health professionals use a questionnaire-based survey to complete a standardized family health file for each participating couple, and also complete medical examinations. Completed files are then converted into electronic records and transferred into the NFPCP medical service information system for storage. This information system was developed by the National Research Institute for Family Planning, and was built with logic checks and instrument interfaces to avoid human errors. Prior to the submission, the data would be rechecked thoroughly.

All medical institutions involved in the NFPCP in Shenzhen have been included in the G6PD enzyme activity screening program since 2013. In order to ensure reliability of the serology examinations, activities in all sites are implemented with standard operating procedures and subject to the annual national external quality assessment. The detailed study design and organization of this project were described elsewhere\(^2\).

This study was an original research based on the NFPCP and the data of 22 sites used were obtained from the NFPCP system. From January 1, 2013 to December 31, 2016, comprising 180 389 eligible females aged 20~49 participated in the NFPCP in Shenzhen, China. Participants with missing data on G6PD enzyme activity, HBV serological examination, tuberculosis history, human immunodeficiency virus (HIV) antibody screening and use of cocaine and other narcotic drugs, as well as those with tuberculosis history or positive HIV antibody screening or cocaine and other narcotic drugs use were excluded. Finally, after excluding other HBV serological test results not intended for this study, data on 124 406 participants were included in the analysis, and they were divided into three categories including the susceptible, immunized, and HBV infected participants, according to the HBV serological test results. Susceptible participants were defined as being HBsAg negative (HBsAg(−)) and hepatitis B surface antibody negative (HBsAb(−)) and hepatitis B e-antigen negative (HBeAg(−)) and hepatitis B e-antibody negative (HBeAb(−)) and hepatitis B core-antibody negative (HBCAb(−)). Immunized participants were defined as being HBsAg(−) and HBsAb positive (HBsAb(+)) and HBeAg(−) and HBeAb(−) and HBCAb(−). HBV infected participants were defined as being HBsAg(+). The susceptible and immunized participants were selected as control groups separately while the HBV infected participants were used as the case group (detailed information of the study population was shown in Fig. 1).

**Data collection.** The standardized questionnaires were completed through face-to-face interviews while medical examinations were conducted by trained health professionals. Demographic characteristics and lifestyle information were collected by questionnaires from the husband and the wife, separately. The variables included were date of birth, nationality, rural/urban inhabitant, migrant population based on the address of household registration, educational level, alcohol consumption, smoke exposure (active or passive smoking), and self-reported history of hepatitis B vaccination. Body weight and height were measured with light indoor clothes without shoes and other accessories based on a standardized protocol. G6PD enzyme activity of erythrocytes, serologic HBV markers, and alanine transaminase (ALT) levels were tested using blood samples collected after at least 8 hours fasting, using ethylenediamine tetra-acetic acid and heparin lithium-anticoagulant vacuum tubes. The samples were stored at 4°C in the freezers and were analyzed within 24 hours. G6PD enzyme activity was tested by a standardized quantitative spectrophotometric analysis. Serologic HBV markers including HBsAg, HBsAb, HBeAg, HBeAb, and HBCAb were tested by enzyme-linked immunosorbent assay.

This study was approved by the Institutional Research Review Board at the National Health Commission and was conducted in accordance with the Declaration of Helsinki. All participants signed written informed consent prior to their participation.
Definition of variables. Variables in this study included demographic characteristics, lifestyle information and serological test results. Age was split into three groups (20–29, 30–39, and 40–49 years old), while nationality was categorized as 'Han' and 'others'. Educational level was categorized into two groups (bachelor degree or above, high school or below). The migrant population was defined as non-permanent population of Guangdong province. Body mass index (BMI) was calculated using weight and height based on the following formula: $\text{BMI} = \frac{\text{weight}}{\text{height}^2} \text{ (kg/m}^2\text{)}$, and then was categorized into four groups as follows: underweight ($<18.5$ kg/m$^2$), normal weight ($18.5–23.9$ kg/m$^2$), overweight ($24.0–27.9$ kg/m$^2$), and obesity ($\geq 28.0$ kg/m$^2$). LG6PD was defined as G6PD enzyme activity below the lower limit of medical reference range based on the quantitative test results (Appendix 1). In this study, husbands with HBsAg(+) were defined as husband's HBV infection.

Statistical analysis. The variables included in this study on the characteristics of the participants in the three groups were presented as count (percentages). $\chi^2$ tests were used for categorical variables among the case group and two control groups. We used logistic regression to estimate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for the association between LG6PD and HBV infection by comparing the HBV infected participants with the susceptible and immunized participants, respectively. In addition to the wife’s own variables, literature has been reported that spouses of HBsAg(+) patients have a higher risk of HBV infection than spouses of HBsAg(-) patients, and there is a higher risk of HBV transmission between spouses24, so the multivariable-adjusted logistic regression was employed to adjust for wife’s demographic characteristics, lifestyle information, BMI, as well as husband’s HBV infection.

Since HBeAg can to some extent indicate the level of HBV infectousness23, we further divided HBV infected participants into two groups (HBsAg(+) HBeAg(-) and HBsAg(+) HBeAg(+)) and compared them with the susceptible and immunized participants separately using multivariable logistic regression, to further identify whether reproductive-age females with LG6PD have a higher prevalence of HBV infection.

To further explore the effect of LG6PD on liver enzyme of participants with HBV infection, we examined ALT elevation as the outcome variable. Participants were divided into four groups according to LG6PD and HBV infection statuses, respectively among the HBV infected and susceptible participants, as well as among the HBV infected and immunized participants. These four groups were: 1) participants with neither HBV infection nor LG6PD (HBsAg(-) HBeAg(-)), 2) participants without HBV infection but with LG6PD (HBsAg(-) L6PD(+)), 3) participants with HBV infection but without LG6PD (HBsAg(+) HBeAg(-) L6PD(-)), and 4) participants with HBV infection combined with LG6PD (HBsAg(+) L6PD(+)). Participants with HBsAg(-) L6PD(-) were selected (among the four groups) as the reference group for comparison. The ORs and 95% CIs were determined to assess the impact of LG6PD on ALT elevation in HBV infected participants. Additionally, we compared the risk of different levels of ALT elevation (slight (ALT ≥ 45 U/L) and moderate (ALT ≥ 60 U/L)) in these four groups.

Subgroup analyses were conducted according to demographic characteristics, lifestyle information, BMI and husband’s HBV infection. Statistical analyses were conducted using Microsoft R Open, version 3.3.3 (Microsoft, Inc, Redmond, WA, USA).
Results
Characteristics of the study population according to HBV infection status. By December 31, 2016, 124,406 eligible females aged 20–49 participated in the NFPCP in Shenzhen, China. The prevalence of LG6PD among the participants was 2.12%. The characteristics of the study population were presented according to HBV infection status (Table 1). Compared with the susceptible participants, HBV infected participants were more likely to be of Han nationality, urban inhabitants, with higher educational level, lower BMIs, and have more smoke exposure, while compared with the immunized participants, they were more likely to be rural inhabitants, with lower educational level, greater BMIs, and have less smoke exposure. Furthermore, compared with the susceptible or immunized groups, HBV infected participants were more likely to be older, resident population, no alcohol consumption, less HBV vaccination injection and with more husband's HBV infection. In particular, the prevalence of LG6PD was significantly higher in the HBV infected group (Table 1).

Association between low G6PD activity level and HBV infection. Among the participants, prevalence of LG6PD were 3.23%, 1.78%, 2.00% in the HBV infected, susceptible control, and immunized control groups, respectively. The ORs of LG6PD with HBV infection were presented in Table 2. In the HBsAg(+) and susceptible control groups, participants with LG6PD had a 71% higher risk of HBV infection (multivariable-adjusted OR: 1.71, 95% CI: 1.45–2.01) than those without LG6PD. In the HBsAg(+) and immunized control groups, compared with participants without LG6PD, those with LG6PD had a 41% higher risk of HBV infection (multivariable-adjusted OR: 1.41, 95% CI: 1.23–1.62).

We further divided HBV infected participants into two groups and found that in the susceptible control group and participants with HBsAg(+) HBeAg(−), the crude OR, husband's HBV infection adjusted OR and multivariable-adjusted OR for HBV infection in participants with LG6PD were 1.79 (95% CI: 1.53–2.09), 1.81 (95% CI: 1.52–2.14), and 1.75 (95% CI: 1.46–2.09), respectively compared to participants without LG6PD. In the susceptible control group and participants with HBsAg(+) HBeAg(+), the crude and adjusted ORs were 2.02 (95% CI: 1.60–2.54), 1.81 (95% CI: 1.40–2.35), and 1.58 (95% CI: 1.21–2.08), respectively. In the immunized control and HBV infected groups, multivariable-adjusted ORs for HBV infection in participants with LG6PD were 1.44 (95% CI: 1.23–1.67) and 1.32 (95% CI: 1.02–1.71), respectively compared to those without LG6PD (Table 3).

Odds ratios for elevated ALT according to low G6PD activity level and HBV infection statuses. Table 4 showed the ORs and their corresponding 95% CIs for elevated ALT according to LG6PD and HBV infection statuses. Among 37,883 pre-pregnant reproductive-age females in the HBV infected and susceptible control groups, 1,496 (3.95%) showed a slight ALT elevation (ALT ≥ 45 U/L). Compared with participants with HBsAg(−) LG6PD(−), participants with HBsAg(+) LG6PD(−) had 184% higher risk of elevated ALT while those with HBsAg(+) LG6PD(+) had 249% higher risk of elevated ALT (Table 4), and the trend was significant (χ² = 418.35, df = 1, p < 0.0001). Among 96,627 pre-pregnant reproductive-age females in the HBV infected and immunized control groups, 2,672 (2.77%) showed slight ALT elevation. Compared with the HBsAg(−) LG6PD(−) group, the ORs for slight ALT elevation were 1.26 (95% CI: 0.94–1.69), 3.48 (95% CI: 3.18–3.80) and 4.28 (95% CI: 2.92–6.28), respectively in the HBsAg(−) LG6PD(+), HBsAg(+) LG6PD(−), and HBsAg(+) LG6PD(+) groups. The results were consistent with the susceptible control group used as a reference, but with higher odds ratios. We further calculated the ORs for moderate ALT elevation (ALT ≥ 60 U/L) and the results were consistent in all statuses with more significant differences in statistics.

Subgroup analyses of the association between low G6PD activity level and HBV infection. Results of subgroup analyses were shown in Fig. 2. We performed logistic regression analysis on age, nationality, urban/rural inhabitants, migrant population, educational level, BMI, alcohol consumption, self-reported history of hepatitis B vaccination, and husband's HBV infection separately. The results showed that multivariable-adjusted ORs in all subgroups were consistent whether we used the susceptible control group or immunized control group as reference.

Discussion
G6PD deficiency is the most common metabolic disorder of red blood cells27, as well as the most widespread form of acute hemolytic anemia27, while HBV infection is a major mother-to-child transmission of disease with a heavy disease burden6. The WHO Working Group recommended that screening for G6PD deficiency in adults by quantitative estimation of the enzyme activity level in red cells, which was considered easy and desirable at the public health level27. In this large population-based study, we used this screening method to explore the relationship between LG6PD and HBV infection among pre-pregnant reproductive-age females. The results showed that females aged 20–49 with LG6PD had a higher risk of HBV infection and that LG6PD might exacerbate ALT elevation in HBV infected females.

Few studies have reported on the association between LG6PD (or G6PD deficiency) and HBV infection, but some findings were consistent with our results. A study from Ghana suggested that patients with viral hepatitis had twice the frequency of G6PD deficiency compared to the general population, and those with G6PD deficiency had a longer and more severe course of hepatitis28. Liu et al.29 found that the prevalence of LG6PD in patients with HBV infection in Guangzhou was 6.60% (20/303), while that of the control group was only 3.37% (20/593). Xiao et al.14 studied 10,626 objects on pre-marital physical examination, and found that those with G6PD deficiency were twice as likely to be infected with HBV as objects without G6PD deficiency, which demonstrated that G6PD deficiency could increase the risk of HBV infection. This study utilized data of a large population and found a significant association between LG6PD and HBV infection. It was interesting that the results on the susceptible control and HBV infected groups were similar to the results on the immunized control and HBV infected groups, but it was more evident when the susceptible control group was used as a reference.
Most researchers explained the potential mechanism by which LG6PD could result in the disorder of oxidative stress and hence, in the malfunctioning of granulocytes. Some researchers suggested that LG6PD could reduce NADPH levels, thus decrease the production of nitric oxide, superoxide and hydrogen peroxide in leucocytes, and weaken the immune function thereof, thereby increasing the susceptibility to pathogens. Wu et al. suggested that G6PD-knockdown cells could produce more reactive oxygen species, and high oxidative stress condition favors viral replication since it promotes viral gene expression. Other mechanism studies showed that LG6PD could affect the redox condition thereby affect the HSCARG-NFκB (a newly identified nuclear factor κB) signaling axis, which could stimulate the expression of antiviral genes and induce susceptibility of the body cells to viruses. Therefore, there are sufficient mechanisms reported in research findings to support the notion that LG6PD could enhance the susceptibility to virus infections.

In this study, after adjusting for covariate variables, the results showed that LG6PD could increase the risk of HBsAg(+) HBeAg(−) and HBsAg(+) HBeAg(+), regardless of whether the susceptible group or the immunized group was selected as reference, which indicated again that LG6PD might be a risk factor for HBV infection. However, multivariable-adjusted ORs for HBsAg(+) HBeAg(−) were greater than those of HBsAg(+) HBeAg(+), which was different from what we expected. Therefore, we further searched relevant literatures and found that there were indeed previous studies whose findings might be consistent with us. Chen et al. investigated the role of G6PD in HBV replication and the possible mechanism of action in liver tissues and cells, and found that G6PD might be an endogenous promoting factor for HBV replication by affecting the expression of HBsAg.

### Table 1. Characteristics of study population according to HBV infection status.

| Variables                              | HBV Infected Participants, N(%) | Susceptible Participants, N(%) | Immunized Participants, N(%) |
|----------------------------------------|---------------------------------|---------------------------------|-----------------------------|
| Total                                   | 10,141 (100.00)                 | 27,756 (100.00)                 | 86,509 (100.00)             |
| Age, y                                  |<0.0001                         |<0.0001                         |<0.0001                      |
| 20–29                                   | 6,161 (60.75)                  | 19,184 (69.12)                 | 56,021 (64.76)             |
| 30–39                                   | 3,672 (36.21)                  | 8,002 (28.83)                  | 28,607 (33.07)             |
| 40–49                                   | 308 (3.04)                     | 570 (2.05)                     | 1,881 (2.17)               |
| Nationality                             |<0.0001                         |<0.0001                         |0.1396                       |
| Han                                     | 9,830 (97.19)                  | 26,436 (95.56)                 | 83,656 (96.92)             |
| Others                                  | 284 (2.81)                     | 1,229 (4.44)                   | 2,659 (3.08)               |
| Rural/urban inhabitant                  |<0.0001                         |<0.0001                         |<0.0001                      |
| Rural                                   | 6,039 (59.55)                  | 19,063 (68.68)                 | 44,699 (51.67)             |
| Urban                                   | 4,102 (40.45)                  | 8,693 (31.32)                  | 41,810 (48.33)             |
| Migrant population                      |<0.0001                         |<0.0001                         |0.05                         |
| Yes                                     | 3,339 (32.93)                  | 14,277 (51.44)                 | 29,390 (33.97)             |
| No                                      | 6,802 (67.07)                  | 13,479 (48.56)                 | 57,119 (66.03)             |
| Educational level                       |<0.0001                         |<0.0001                         |<0.0001                      |
| Bachelor degree or above                | 6,074 (60.45)                  | 13,886 (50.50)                 | 59,746 (69.56)             |
| High school or below                    | 3,974 (39.55)                  | 13,611 (49.50)                 | 26,144 (30.44)             |
| Body mass index, kg/m²                  |<0.0001                         |<0.0001                         |<0.01                        |
| Underweight (<18.5)                     | 2,098 (21.10)                  | 5,362 (19.69)                  | 18,006 (21.19)             |
| Normal weight (18.5−)                   | 6,723 (67.62)                  | 18,233 (66.66)                 | 57,900 (68.13)             |
| Overweight (24.0−)                      | 913 (9.18)                     | 2,943 (10.81)                  | 7,672 (9.03)               |
| Obesity (≥28.0)                         | 209 (2.10)                     | 691 (2.54)                     | 1,401 (1.65)               |
| Alcohol consumption                     |<0.0001                         |<0.0001                         |<0.0001                      |
| Yes                                     | 1,654 (16.35)                  | 5,603 (20.25)                  | 18,610 (21.58)             |
| No                                      | 8,462 (83.65)                  | 22,068 (79.75)                 | 57,624 (78.42)             |
| Smoke exposure                          |<0.0001                         |<0.0001                         |<0.001                       |
| Yes                                     | 3,580 (35.30)                  | 9,223 (33.23)                  | 32,072 (37.07)             |
| No                                      | 6,561 (64.70)                  | 18,530 (66.77)                 | 54,434 (62.93)             |
| Self-reported history of hepatitis B vaccination |<0.0001                         |<0.0001                         |<0.0001                      |
| Yes                                     | 2,665 (26.43)                  | 10,804 (39.10)                 | 51,040 (59.21)             |
| No                                      | 7,418 (73.57)                  | 16,830 (60.90)                 | 35,157 (40.79)             |
| Husband’s HBV infection                 |<0.0001                         |<0.0001                         |<0.0001                      |
| Yes                                     | 1,399 (16.14)                  | 1,771 (7.86)                   | 8,875 (12.02)              |
| No                                      | 7,270 (83.86)                  | 20,729 (92.14)                 | 64,927 (87.98)             |
| Low G6PD activity level                 |<0.0001                         |<0.0001                         |<0.0001                      |
| Yes                                     | 328 (3.23)                     | 494 (1.78)                     | 1,728 (2.00)               |
| No                                      | 9,813 (96.77)                  | 27,262 (98.22)                 | 84,781 (98.00)             |
of genes related to the type I interferon pathway. Hu et al.34 put forward through research that G6PD suppression could lead to reduced concentrations of HbsAg and HBsAg in supernatant. Ding35 also reported that HBG6PD might exacerbate ALT elevation among HBV infected participants. Some studies have suggested that G6PD deficiency could expedite the repair of hepatocytes damaged by viral hepatitis as a result of increased oxidative damage to hepatocytes because of glutathione depletion, thus causing liver malfunction. Zheng et al.26 proposed that G6PD deficiency could aggravate hepatitis, and was prone to erythrocyte hemolysis which could result in liver damage. Another study27 suggested that prolonged jaundice from hepatitis could be attributed to G6PD deficiency. All of these studies might indirectly support the finding that LG6PD had effects on liver damage of patients with hepatitis.

We believe our research has important public health and clinical implications because G6PD deficiency and HBV infection and the related complications are primary public health threats worldwide.89 Reproductive-age females with LG6PD combined with HBV infection are high risk population, especially during the pre-pregnancy and pregnancy periods. Therefore, effective interventions should be taken in this stage to ensure maternal and child health. Firstly, pregnancy could aggravate the liver burden in females with HBV infection and HBV infection could result in spontaneous abortion, preterm birth and other adverse outcomes.15-17, while G6PD deficiency could result in spontaneous abortion, intrauterine fetal death, stillbirth, fetal abnormality and other adverse outcomes.27,28 Hence, liver enzyme monitoring, prenatal examination, and careful use of oxidative drugs (such as aspirin, phenacetin, and sulfadiazine) to avoid hemolytic anemia and increase liver cell damage should be strengthened for pregnant women who combined these two diseases. When these high-risk women are delivered, the newborns should also be administered with hepatitis B immunoglobulin early enough to effectively block mother-to-child transmission, and G6PD screening should also be performed simultaneously. Moreover, hepatitis B vaccination should be strengthened during childhood.

To our knowledge, our study was the first large-scale population study to explore the association between LG6PD and HBV infection in pre-pregnancy females in China, and the results in part provided some references of the association between these two diseases. However, some limitations should also be declared. First, due to the results of two screening methods of G6PD enzyme activity quantitative estimation (NADP + REDOX enzyme

| Low G6PD activity level | HBV infected participants and Susceptible participants | Immunized participants vs HBV infected participants |
|-------------------------|------------------------------------------------------|-----------------------------------------------------|
|                         | Crude OR (95% CI) | Husband's HBV infection Adjusted† OR (95% CI) | Multivariable-Adjusted‡ OR (95% CI) | Crude OR (95% CI) | Husband's HBV infection Adjusted† OR (95% CI) | Multivariable-Adjusted‡ OR (95% CI) |
| No                      | Ref            | Ref                                          | Ref                                       | Ref            | Ref                          | Ref                                   |
| Yes                     | 1.84 (1.60–2.12) | 1.71 (1.45–2.01) | 1.64 (1.45–1.85) | 1.60 (1.41–1.82) | 1.41 (1.23–1.62)            |                                         |
|                         |                |                                              |                                          |                |                             |                                         |
| Table 2. Association between low G6PD activity level and HBV infection. OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; G6PD, glucose-6-phosphate dehydrogenase; Ref, reference. †Husband's HBV infection Adjusted OR was adjusted for husband's HBV infection. ‡Multivariable-Adjusted OR was adjusted for age, nationality, rural/urban inhabitants, migrant population, educational level, BMI, alcohol consumption, smoke exposure, self-reported history of hepatitis B vaccination, husband's HBV infection. 

| Low G6PD activity level | HBV infected participants and Susceptible participants | Immunized participants vs HBV infected participants |
|-------------------------|------------------------------------------------------|-----------------------------------------------------|
|                         | Crude OR (95% CI) | Husband's HBV infection Adjusted† OR (95% CI) | Multivariable-Adjusted‡ OR (95% CI) | Crude OR (95% CI) | Husband's HBV infection Adjusted† OR (95% CI) | Multivariable-Adjusted‡ OR (95% CI) |
| No                      | Ref            | Ref                                          | Ref                                       | Ref            | Ref                          | Ref                                   |
| Yes                     | 1.79 (1.53–2.09) | 1.75 (1.46–2.09) | 1.60 (1.38–1.85) | 1.44 (1.23–1.67) | 1.40 (1.23–1.62)            |                                         |
|                         |                |                                              |                                          |                |                             |                                         |
| Table 3. Association between low G6PD activity level and HBV infection according to HBsAg status. OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HBsAg, hepatitis B e-antigen; G6PD, Glucose-6-phosphate dehydrogenase; Ref, reference. †Husband's HBV infection Adjusted OR was adjusted for husband's HBV infection. ‡Multivariable-Adjusted OR was adjusted for age, nationality, rural/urban inhabitants, migrant population, educational level, BMI, alcohol consumption, smoke exposure, self-reported history of hepatitis B vaccination, husband's HBV infection.
method and G6PD/6PGD ratio method) were similar, we defined LG6PD as a categorical variable according to whether it was below the lower limit of medical reference range. Thus, we could not stratify G6PD activity levels into more specific groups for quantitative analysis. Second, instead of using HBV DNA to directly verify the association between LG6PD and HBV replication, we used HBeAg as an indicator to indirectly study the association between LG6PD and HBV infectiousness. Third, we only used once serological test result to define ALT elevation, other liver enzymes were not measured in our study, and the data of whether the participants with HBV infection were receiving antiviral therapy was not collected completely. This might cause misclassification bias in the analysis of the effect of LG6PD on liver enzyme among HBV infected females. Lastly, the causal relationship between LG6PD and HBV infection could not be proved by a cross-sectional study. Prospective cohort studies and animal model studies should be conducted to further verify the association between the two diseases in future.

Table 4. Odds ratios for elevated ALT according to low G6PD activity level and HBV infection statuses. N, number; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; LG6PD, low Glucose-6-phosphate dehydrogenase activity level; Ref, reference.

| Subgroup | N of events | Multivariate-adjusted OR(95% CI) | N of events | Multivariate-adjusted OR(95% CI) |
|----------|-------------|----------------------------------|-------------|----------------------------------|
| Age      |             |                                   |             |                                   |
| <30      | 537         | 1.57(1.28–1.93)                   | 1 255       | 1.38(1.15–1.65)                   |
| ≥30      | 285         | 1.96(1.59–2.42)                   | 861         | 1.65(1.37–2.00)                   |
| Nationality |           |                                   |             |                                   |
| Han      | 762         | 1.70(1.44–2.01)                   | 1 949       | 1.42(1.21–1.65)                   |
| Others   | 57          | 1.86(1.44–2.42)                   | 99          | 1.12(0.53–2.34)                   |
| Rural/Urban inhabitant | |                                   |             |                                   |
| Rural    | 562         | 1.67(1.35–2.05)                   | 1 160       | 1.38(1.15–1.65)                   |
| Urban    | 260         | 1.73(1.33–2.26)                   | 896         | 1.42(1.15–1.75)                   |
| Migrant population | |                                   |             |                                   |
| Yes      | 237         | 1.79(1.26–2.54)                   | 430         | 1.51(1.02–2.20)                   |
| No       | 555         | 1.68(1.39–2.02)                   | 1 626       | 1.37(1.17–1.60)                   |
| Educational level |         |                                   |             |                                   |
| Bachelor degree or above | 354     | 1.62(1.29–2.04)                   | 1 216       | 1.34(1.11–1.61)                   |
| High school or below | 439     | 1.80(1.42–2.27)                   | 819         | 1.48(1.20–1.81)                   |
| Body Mass Index, kg/m² |   |                                   |             |                                   |
| Underweight (≤18.5) | 177     | 1.08(0.77–1.53)                   | 427         | 1.10(0.80–1.51)                   |
| Normal weight (18.5–24.9) | 516    | 1.99(1.62–2.43)                   | 1 388       | 1.42(1.21–1.67)                   |
| Overweight (≥25) | 90      | 1.79(1.09–2.94)                   | 1 712       | 2.15(1.40–3.30)                   |
| Obesity (≥30) | 20      | 1.54(0.45–5.20)                   | 33          | 1.67(0.60–4.44)                   |
| Alcohol consumption |   |                                   |             |                                   |
| Yes      | 142         | 1.92(1.29–2.86)                   | 384         | 1.57(1.12–2.19)                   |
| No       | 677         | 1.66(1.30–2.10)                   | 1 696       | 1.48(1.19–1.86)                   |
| Smoke exposure |   |                                   |             |                                   |
| Yes      | 269         | 1.76(1.34–2.33)                   | 747         | 1.37(1.09–1.72)                   |
| No       | 553         | 1.66(1.37–2.00)                   | 1 309       | 1.43(1.19–1.70)                   |
| Self-reported history of hepatitis B vaccination | |                                   |             |                                   |
| Yes      | 260         | 1.90(1.43–2.53)                   | 1 024       | 1.69(1.32–2.15)                   |
| No       | 558         | 1.63(1.33–1.99)                   | 1 027       | 1.30(1.03–1.63)                   |
| Husband’s HBV infection | |                                   |             |                                   |
| Yes      | 90          | 1.54(0.99–2.41)                   | 273         | 1.36(0.97–1.99)                   |
| No       | 597         | 1.74(1.46–2.07)                   | 1 513       | 1.42(1.22–1.65)                   |

Figure 2. Subgroup analysis of the association between low G6PD activity level and HBV infection. N, number; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; G6PD, Glucose-6-phosphate dehydrogenase. Note: In this figure N of events showed the count of LG6PD participants with HBV infection, and all of the subgroup analysis models were adjusted for age, nationality, rural/urban inhabitants, migrant population, higher educational level, BMI, alcohol consumption, smoke exposure, self-reported history of hepatitis B vaccination and husband’s HBV infection.
References

1. Cappellini, M. D. & Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet* **371**, 64–74 (2008).

2. Gotsman, I. & Muszkat, M. Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis. *Journal of virology and virology* **16**, 1239–1243 (2001).

3. Department of maternal and child health service in Chinese National Health and Family Planning commission. The annual report of maternal and child health monitoring in 2014. 6 (National health and Family Planning commision, 2016).

4. Nóbrega e Square, S. et al. G6PD protects from oxidative damage and improves healthspan in mice. *Nature communications* **7**, 10894 (2016).

5. Tsai, K. J. et al. Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. *FEBS letters* **436**, 411–414 (1998).

6. Wu, Y. H. et al. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. *The Journal of infectious diseases* **197**, 812–816 (2008).

7. Chen, Z. W. et al. Role of glucose-6-phosphate dehydrogenase in hepatitis B virus replication and its possible mechanism of action. *Chin J Hepatol* **24**, 347–351 (2016).

8. Zhang, L. et al. Status of HBsAg seroprevalence in 15 million rural couples in China: a cross-sectional study. *Sci Rep* **7**, 42822 (2017).

9. Schöwe, A., Horn, J., Mikolajczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* **386**, 1546–1555 (2015).

10. Trepčo, C., Chan, H. L. & Lok, A. Hepatitis B virus infection. *The Lancet* **384**, 2053–2063 (2014).

11. World Health Organization. Global Hepatitis Report. 2017. (World Health Organization, 2017).

12. China State Statistics Bureau. *China statistics almanac* in 2016. (China statistics press, 2016).

13. Liang, X. et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. *Vaccine* **31**(Suppl 9), i21–i28 (2013).

14. Gufier, X., Xu, J. Z., Xue, J. Z. & Jian, H. Would Glucose-6-phosphate dehydrogenase deficiency increase prevalence of HBV? *Chinese Journal of Birth Health & Heredity* (92), 96 (1997).

15. Ye, F. et al. The effect of hepatitis B virus infected embryos on pregnancy outcome. *European journal of obstetrics, gynecology, and reproductive biology* **172**, 10–14, https://doi.org/10.1016/j.ejogrb.2013.10.002 (2014).

16. Cui, A. M. et al. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. *BMJ pregnancy and infant* **16**, 87 (2016).

17. Stokkeland, K. et al. Pregnancy outcome in more than 5000 births with women with viral hepatitis: a population-based cohort study in Sweden. *Eur J Epidemiol* (2017).

18. Zhongling, C., et al. Glucose-6-phosphate deficiency screening of reproductive population in Baan District. *Chin J Reprod Heal 17*, 240 (2006).

19. Zhili, W., Xiaoli, H. & Weiyong, Z. Analysis on screening of G6PD deficiency among 3 465 fertile women in Longgang district of Shenzhen city. *Jin Med Med J 32*, 2616–2617 (2011).

20. Ting, G. et al. Investigation on the status of HBV infection in pregnant couples in Shenzhen city. *Chinese Journal of Family Planning* **25**, 274–277 (2017).

21. Zhang, S., Wang, Q. & Shen, H. The design, implementation and significance of National Free Pre-conception Check-up Projects in China. *Natl Med J China* **85**, 162–165 (2015).

22. Yang, Y. et al. Association of Husband Smoking With Wife’s Hypertension Status in Over 5 Million Chinese Females Aged 20 to 49 Years. *J Am Heart Assoc* **6**, e004924 (2017).

23. Liu, J. et al. Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: An observational study. *Journal of viral hepatitis* **24**, 679–686, https://doi.org/10.1111/j.vlh.12893 (2017).

24. Sun, A. W. et al. Study on the risk of HBV infection among spouses of HBsAg carriers. *Zhonghua liu xing bing xue za zhi* **34**, 214–217 (2013).

25. Nabhazadeh, S. H. & Anshiravanani, A. The prevalence of G6PD deficiency in blood transfusion recipients. *Hematology (Amsterdam, Netherlands)* **12**, 85–88 (2007).

26. Luzzatto, L. & Arce, F Favisism and Glucose-6-Phosphate Dehydrogenase Deficiency. *N Engl J Med* **378**, 60–71 (2018).

27. World Health Organization. Glucose-6-phosphate dehydrogenase deficiency: WHO Working Group. *Bull World Health Organ* **67**, 601–611 (1989).

28. Morrow, R. H. Jr., Smetana, H. F., Sai, F. T. & Edgcomb, J. H. Unusual features of viral hepatitis in Accra, Ghana. *Annals of internal medicine* **68**, 1250–1264 (1968).

29. Yunzhou, L., Xuebing, Z. & Yang, X. Clinical implication of glucose-6-phosphate dehydrogenase detection in patients with viral hepatitis. *Journal of Xinhua Medical* **23**, 307–309 (2008).

30. Cooper, M. R. et al. Complete Deficiency of Leucocyte Glucose-6-Phosphate Dehydrogenase with Defective Bactericidal Activity. *Journal of Clinical Investigation* **51**, 769–778 (1972).

31. Vives Corrons, J. L. et al. Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). *Blood* **92**, 1250–1264 (1998).

32. de Oliveira-Junior, E. B., Bustamante, J., Newburger, P. E. & Condino-Neto, A. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbialidal activity of phagocytes. *Scand J Immunol* **73**, 420–427, https://doi.org/10.1111/j.1365-3083.2010.02501.x (2011).

33. Wu, Y. H. et al. Glucose-6-Phosphate Dehydrogenase Enhances Antiviral Response through Downregulation of NADPH Sensor HSCARG and Upregulation of NF–κB Signaling. *Viruses* **7**, 6689–6700, https://doi.org/10.3390/v7122296 (2015).

34. Hu, H. et al. Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells. *American journal of physiology. Gastrointestinal and liver physiology* **307**, G611–622, https://doi.org/10.1152/ajpgi.00160.2014 (2014).

35. Dang, X. Screening of HBV-related hepatocellular carcinoma biomarker and mechanism of G6PD in HBV replication PhD thesis, Changqing Medical University, (2013).

36. Mi, Z. & Jianming, L. Relationship between Glucose-6-Phosphate Dehydrogenase Deficiency and Viral Hepatitis in Guangxi Area. *J Appl Clin Pediatr* **22**, 1459–1460 (2007).

37. Tomcheva, D. & Tzoneva, M. Prenatal selection and fetal development disturbances occurring in carriers of G6PD deficiency. *Human genetics* **69**, 88 (1985).

38. Nicoll, C. J., Zielesinski, J., Tsui, L. C. & Wells, P. G. An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **14**, 111–127 (2000).

39. Chunlin, X. Comparison of two G6PD enzyme test system. *Chin Prac Med* **05**, 63–64 (2010).
Acknowledgements
This study was supported by the 13th Five-Year Plan, National Key Research and Development Program of China (grant No. 2016YFC1000307), the National Human Genetic Resources Sharing Service Platform (grant No. 2005DKA21300) and the National Population and Reproductive Health Science Data Center (grant No. 2005DKA32408), People’s Republic of China. We thank health workers and countless participants throughout Shenzhen in the NFPCP for their great efforts and collaboration.

Author Contributions
J.Z. designed and supervised the study. J.Z., X.Z. searched the literature, analyzed the data, interpreted the results, and drafted the manuscript. T.G., W.H. and X.H. led the data collection and laboratory testing. Q.D., B.W., D.Q., X.Y. and Y.Z. helped to revise the draft. H.Z., Y.W. and Z.P. were responsible for data collection and management. X.M. supervised the study process and provided overall guidance. J.Z. and X.Z. contributed equally to this research paper. All authors contributed to manuscript composition.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-40354-7.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019